Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.75 |
| ▸ | MAPK10 | P53779 | 3/20 | 0.75 |
| ▸ | MAPT | P10636 | 2/20 | 0.75 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.72 |
| ▸ | POLB | P06746 | 4/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6169266 | 0.86 | RAB9A (0.74) | HPGDALDH1A1KDM4EMAPK10MAPT | |
| SCHEMBL14104417 | 0.86 | HPGD (0.79) | HPGDALDH1A1KDM4EMAPK10MAPT | |
| SCHEMBL9070025 | 0.84 | L3MBTL1 (1.00) | HPGDALDH1A1KDM4EMAPK10MAPT | |
| SCHEMBL6258773 | 0.82 | MAPT (0.65) | HPGDALDH1A1KDM4EMAPK10MAPT | |
| SCHEMBL14104161 | 0.82 | HPGD (0.73) | HPGDALDH1A1KDM4EMAPK10MAPT | |
| SCHEMBL890758 | 0.82 | POLB (1.00) | HPGDALDH1A1KDM4EMAPK10MAPT | |
| SCHEMBL4077586 | 0.82 | L3MBTL1 (0.84) | HPGDALDH1A1KDM4EMAPK10MAPT | |
| SCHEMBL25207565 | 0.82 | MAPK10 (1.00) | HPGDALDH1A1KDM4EMAPK10MAPT | |
| SCHEMBL6279161 | 0.82 | PKM (0.52) | HPGDALDH1A1KDM4EMAPK10MAPT | |
| SCHEMBL12132465 | 0.81 | HPGD (0.71) | HPGDALDH1A1KDM4EMAPK10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0999834-B1 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2005-10-12 | — | — | EP | disclosed |
| EP-1019045-B1 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1007037-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2004-10-06 | — | — | EP | disclosed |
| US-6677369-B2 | CARBOXIMIDAMIDE DERIVATIVE ANTICOAGULANTS INHIBIT FACTOR XA | ELI LILLY AND COMPANY | 2004-01-13 | — | — | US | disclosed |
| US-20030195223-A1 | An anticoagulant, blood inhibitor of factor Xa, a N1-amidinebenzoyl- N2-benzoyl-1,2-benzenediamine derivatives; chemical intermediates | BEIGHT DOUGLAS WADE (US) | 2003-10-16 | — | — | US | disclosed |
| US-6586459-B2 | Inhibitors of factor Xa; for example 3-(4-tert-butylbenzoyl)amino-N-(4-methoxyphenyl)-2-thiophenecarboxamide | BEIGHT DOUGLAS WADE (US) | 2003-07-01 | — | — | US | disclosed |
| US-6583173-B2 | Useful as anticoagulants in mammals; inhibitors of factor Xa | ELI LILLY AND COMPANY | 2003-06-24 | — | — | US | disclosed |
| US-20030078431-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2003-04-24 | — | — | US | disclosed |
| US-6500851-B2 | ANTICOAGULANT IN MAMMLS | ELI LILLY AND COMPANY | 2002-12-31 | — | — | US | disclosed |
| US-20020173518-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2002-11-21 | — | — | US | disclosed |
| EP-1019045-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2002-07-03 | — | — | EP | disclosed |
| US-20020072531-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2002-06-13 | — | — | US | disclosed |
| US-20020049234-A1 | Antithrombotic agents | BEIGHT DOUGLAS WADE (US) | 2002-04-25 | — | — | US | disclosed |
| US-6372759-B1 | BLOOD COAGULATION FACTOR XA FOR MAMMALS | ELI LILLY AND COMPANY | 2002-04-16 | — | — | US | disclosed |
| US-6313151-B1 | AS INHIBITORS OF FACTOR XA AND ARE USED AS ANTICOAGULANTS IN MAMMALS | ELI LILLY AND COMPANY | 2001-11-06 | — | — | US | disclosed |
| EP-1019045-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-1007037-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999000128-A9 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 1999-08-05 | — | — | WO | disclosed |
| WO-1999000127-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
| WO-1999000128-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195223-A1 | An anticoagulant, blood inhibitor of factor Xa, a N1-amidinebenzoyl- N2-benzoyl-1,2-benzenediamine derivatives; chemical intermediates | F12, F11, F2 | HPGD 690/4885ALDH1A1 1095/4885KDM4E 2806/4885 |
| US-20020173518-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | HPGD 225/4885ALDH1A1 323/4885KDM4E 4316/4885 |
| US-20020072531-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | HPGD 225/4885ALDH1A1 323/4885KDM4E 4316/4885 |
| US-20020049234-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | HPGD 225/4885ALDH1A1 323/4885KDM4E 4316/4885 |
| US-20030078431-A1 | Antithrombotic agents | SERPINC1, TFPI, F11 | HPGD 225/4885ALDH1A1 323/4885KDM4E 4316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.